Challenges and Trends in Vaccine Manufacturing - An evaluation of the technologies and process parameters needed to develop a safe, effective, and economically efficient vaccine. This article is part

ADVERTISEMENT

Challenges and Trends in Vaccine Manufacturing
An evaluation of the technologies and process parameters needed to develop a safe, effective, and economically efficient vaccine. This article is part of a special section on vaccines.


BioPharm International Supplements
Volume 24, Issue 10, pp. s3-s11

REFERENCES

1. S. Plotkin, W. Orenstein, P. Offit, Vaccines (Saunders, Philadelphia, 5th ed. 2008).

2. C. Scott, supplement to BioProcess Intl. 6 (6) s12–s18 (2008).

3. S. Fetzer, supplement to BioPharm Intl. 21 (1) s1–s6 (2008).

4. C.P. Steffy and L. Rosin, BioProcess Intl. 2 (4), s48–s57 (2004).

5. P. Holland-Moritz, BioPharm Bulletin (June 2006).

6. S. Srivastava, Vaccine World Summit March 1–3 (2011).

7. S.S. Ozturk, Cytotechnology 22, 3–16 (1996).

8. A. Heuer, The Bridge Editor's Note 36 (3) 3 (2006).

9. B. Kalbfuss et al., Jrnl. of Membrane Sci. 299, 251–260 (2007).

10. A. Karger, J. Schmidt, and T.C. Metten-leiter, Jrnl. Virol. 72, 7341–7348 (1998).

11. T. Vicente et al., Jrnl. of Membrane Sci. 311, 270–283 (2008).

12. T. Vicente et al., Gene Therapy 16, 766–775 (2009).

13. J. Tal, J Biomedical Sci. 7, 279–291 (2000).

14. WHO, Temperature Sensitivity of Vaccines, http://whqlibdoc.who.int/hq/2006/WHO_IVB_06.10_eng.pdf, accesses Sept. 6, 2011.

15. D. Chen and D. Kristensen, Expert Rev. Vaccines 8 (5), 547–557 (2009).

16. E. Boer, supplement to BioProcess Intl. 6 (10), 38–40 (2008).

17. N.W. Baylor, supplement to BioPharm Intl. 20 (8) (2007).

18. H. Pora, BioPharm Intl. 19 (6) (2006).

19. L. Leveen and S. Cox, presentation at IBC's 5th International Single-Use Applications for Biopharmaceutical Manufacturing (San Diego, 2008).

20. D. Newman and S. Walker, presentation at IBC's 5th International Single-Use Applications for Biopharmaceutical Manufacturing (San Diego, 2008).

21. G. Healy, Microbiologist 3, 28–30 (2006).

22. C. Scott, supplement to BioProcess Intl. 9, 3–42 (2010).

ACKNOWLEDGMENT

The author would like to acknowledge colleagues from Sartorius Stedim Biotech, Mahesh Prashad and Frank Meyeroltmanns for sharing their knowledge and designing the generic schemes for platform processes in vaccine manufacturing. The author appreciates the support of Dr. Uwe Gottschalk, vice-president of purification technologies at Sartorius Stedim Biotech. The author would also like to acknowledge Anurag S. Rathore, PhD, a faculty member at the Indian Institute of Delhi, India, for his editorial assistance with this paper. Rathore is a member of BioPharm International's Editorial Advisory Board and the author of the journal's series on the Elements of Biopharmaceutical Production.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
October 22, 2014
Roche to Expand and Improve its Basel Site
October 22, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
October 22, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here